Sugi Predict

Sugi Predict / Compounds / SCHEMBL23323478

SCHEMBL23323478

SCHEMBL23323478

CC(C)N1CC2(CCN(C(=O)N(C)C(C)C)CC2)C1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 8/20 0.39
▸ HRH3 Q9Y5N1 3/20 0.37
▸ CYP2D6 P10635 11/20 0.37
▸ CYP2C9 P11712 8/20 0.37
▸ CYP2C19 P33261 6/20 0.37
▸ TSHR P16473 5/20 0.37
▸ CYP1A2 P05177 7/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ HIF1A Q16665 2/20 0.35
▸ USP2 O75604 4/20 0.33
▸ MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23323568 0.92 HRH3 (0.39) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL23325421 0.90 HRH3 (0.39) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL23323567 0.88 CYP2D6 (0.39) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL23323569 0.88 CYP3A4 (0.44) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL23324887 0.87 HRH3 (0.43) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL19505125 0.86 CYP3A4 (0.41) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL25884737 0.85 HRH3 (0.36) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL25884739 0.84 HRH3 (0.31) HRH3
SCHEMBL25135384 0.79 CYP3A4 (0.58) CYP3A4HRH3CYP2D6CYP2C9CYP2C19
SCHEMBL23323571 0.78 HRH3 (0.42) CYP3A4HRH3CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-11566007-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-01-31 — — US disclosed
US-20210130303-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566007-B2 Ras inhibitors KRAS, NRAS, HRAS CYP3A4 3780/4885HRH3 3696/4885CYP2D6 3178/4885
US-20230234929-A1 RAS INHIBITORS KRAS, NRAS, HRAS CYP3A4 3780/4885HRH3 3696/4885CYP2D6 3178/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR CYP3A4 4873/4885HRH3 3890/4885CYP2D6 4714/4885
US-20210130303-A1 RAS INHIBITORS KRAS, NRAS, HRAS CYP3A4 3780/4885HRH3 3696/4885CYP2D6 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.